ATE440828T1 - 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen - Google Patents

4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen

Info

Publication number
ATE440828T1
ATE440828T1 AT04811612T AT04811612T ATE440828T1 AT E440828 T1 ATE440828 T1 AT E440828T1 AT 04811612 T AT04811612 T AT 04811612T AT 04811612 T AT04811612 T AT 04811612T AT E440828 T1 ATE440828 T1 AT E440828T1
Authority
AT
Austria
Prior art keywords
furan
dihydro
oxo
derivatives
compounds
Prior art date
Application number
AT04811612T
Other languages
English (en)
Inventor
Jae-Kyu Jung
Graeme Semple
Benjamin R Johnson
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of ATE440828T1 publication Critical patent/ATE440828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04811612T 2003-11-21 2004-11-18 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen ATE440828T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52426903P 2003-11-21 2003-11-21
PCT/US2004/038920 WO2005051937A2 (en) 2003-11-21 2004-11-18 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof

Publications (1)

Publication Number Publication Date
ATE440828T1 true ATE440828T1 (de) 2009-09-15

Family

ID=34632884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811612T ATE440828T1 (de) 2003-11-21 2004-11-18 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen

Country Status (10)

Country Link
US (2) US20070093545A1 (de)
EP (1) EP1701947B1 (de)
JP (1) JP2007512346A (de)
CN (1) CN1882557A (de)
AT (1) ATE440828T1 (de)
AU (1) AU2004293415A1 (de)
CA (1) CA2545823A1 (de)
DE (1) DE602004022864D1 (de)
ES (1) ES2331521T3 (de)
WO (1) WO2005051937A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
KR100826108B1 (ko) * 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
US20110082202A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
CN109416406B (zh) * 2016-07-05 2023-06-20 深圳帧观德芯科技有限公司 具有不同热膨胀系数的接合材料

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169202A (en) * 1978-06-05 1979-09-25 American Home Products Corporation Process for preparing 4,5-dihydro-4-oxofuran-2-carboxylic acid derivatives
US4244958A (en) * 1979-05-10 1981-01-13 American Home Products Corporation Hypolipidemic derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003300014A1 (en) 2002-10-10 2004-05-04 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2004041274A1 (en) 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
PE20050483A1 (es) * 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
EP1811996A1 (de) * 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von hitzewallungen und lipidabhängigen störungen mit niacin-rezeptor-teilagonisten
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
JP2008538277A (ja) 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
EP1899304A1 (de) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazol-3-carbonsäurederivate als agonisten des g-protein-gekoppelten rezeptors (gpcr) rup38 zur behandlung von stoffwechselerkrankungen damit
WO2007021744A1 (en) 2005-08-10 2007-02-22 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Also Published As

Publication number Publication date
ES2331521T3 (es) 2010-01-07
DE602004022864D1 (de) 2009-10-08
US7803837B2 (en) 2010-09-28
US20070161701A1 (en) 2007-07-12
EP1701947A2 (de) 2006-09-20
EP1701947B1 (de) 2009-08-26
CN1882557A (zh) 2006-12-20
AU2004293415A1 (en) 2005-06-09
WO2005051937A8 (en) 2006-08-31
CA2545823A1 (en) 2005-06-09
JP2007512346A (ja) 2007-05-17
WO2005051937A2 (en) 2005-06-09
US20070093545A1 (en) 2007-04-26
WO2005051937A3 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
DE602005015397D1 (de) Leuchtstoff, Verfahren zu seiner Herstellung und diesen Leuchtstoff verwendende Lichtquelle
DE602004030239D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
ATE495177T1 (de) Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
ATE309182T1 (de) Gleichmässig gefärbte gerüstkeramik sowie färbelösung
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
DE112004000210D2 (de) Beschichteter Leuchtstoff, lichtemittierende Vorrichtung mit derartigem Leuchtstoff und Verfahren zu seiner Herstellung
ATE529793T1 (de) Vorrichtung und verfahren zur kontinuierlichen herstellung von farben mit automatischer anpassung der farbe
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
DE60137386D1 (de) Phosphor-Dünnfilm, Verfahren zur Herstellung und EL-Folie
DE60316152D1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
DE502006002680D1 (de) Verfahren zur herstellung von feinteiligem c.i. pigment red 254
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
DE60210695D1 (de) Farbstoff zum Färben von Kontaktlinsen und Verfahren zur Herstellung gefärbter Kontaktlinsen
DE50209217D1 (de) Verfahren zur Herstellung von Polyisocyanaten der Diphenylmethanreihe mit vermindertem Farbwert
ATE440828T1 (de) 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
AU2003256100A1 (en) Coloring method of natural leather, and colored natural leather using the same
DE60313157D1 (de) Ein verfahren zur herstellung von clopidogrel
ATE301127T1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
DE502004002371D1 (de) Verfahren zur herstellung von transparenten pigmentzubereitungen auf basis von perylen-3,4,9,10-tetracarbons urediimid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties